aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.15372/ATER20200106ateroskleroz-357Research ArticleОБЗОРЫREVIEWSЭффекты биомаркеров, секретируемых висцеральными адипоцитами, на сердечно-сосудистую системуEffects of biomarkers secreted by visceral adipocites on the cardiovascular systemОблауховаВ. И.OblaukhovaV. I.

Облаухова Вероника Игоревна – аспирант

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

nikamedicine@mail.ruРагиноЮ. И.RaginoYu. I.

Рагино Юлия Игоревна – д-р мед. наук, проф. РАН, чл.-корр. РАН, руководитель НИИТПМ – филиал ИЦиГ СО РАН

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

630089, Novosibirsk, Boris Bogatkov str., 175/1

ragino@mail.ruНИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАНРоссияResearch Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RASRussian Federation2020240420201613352Copyright © Облаухова В.И., Рагино Ю.И., 20202020Облаухова В.И., Рагино Ю.И.Oblaukhova V.I., Ragino Y.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/357

В литературном обзоре освещены результаты проведенных в мире исследований последних лет, посвященных изучению биохимических факторов, секретируемых висцеральными адипоцитами и влияющих на деятельность сердечно-сосудистой системы. Описаны результаты исследований таких биомолекул, как лептин, адипонектин, резистин, фактор некроза опухоли альфа, интерлейкин-1, интерлейкин-6, интерлейкин-8, интерлейкин-10, тканевой фактор, липопротеинлипаза, аполипопротеин Е, факторы комплемента, ингибитор активатора плазминогена 1 типа, висфатин, протеины ренин-ангиотензиновой системы, апелин, оментин, моноцитарно-хемоаттрактантный протеин 1 типа, ретинол-связывающий протеин 4 типа.

The literature review highlights the results of recent studies of the world over the invectigations of biochemical factors secreted by visceral adipocytes and affecting the activity of the cardiovascular system. The results of studies of biomolecules such as leptin, adiponectin, resistin, tumor necrosis factor alpha, interleukin 1, interleukin 6, interleukin 8, interleukin 10, tissue factor, lipoprotein lipase, apolipoprotein E, complement factors, plasminogen activator inhibitor type 1, visfatin, proteins of angiotensin system, apelin, omentin, monocyte chemoattractant type 1 protein, retinol-binding protein of type 4 are described.

ишемическая болезнь сердцависцеральный адипоцитбиомаркерыcoronary heart diseasevisceral adipocytebiomarkersReferencesSchäffler A., Müller-Ladner U., Schölmerich J., et al. Role of adipose tissue as an inflammatory organ in human diseases // Endocrine Rev. 2006. Vol. 27, N 5. P. 449–467. DOI: 10.1210/er.2005-0022Schäffler A., Müller-Ladner U., Schölmerich J., et al. Role of adipose tissue as an inflammatory organ in human diseases // Endocrine Rev. 2006. Vol. 27, N 5. P. 449–467. DOI: 10.1210/er.2005-0022Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ // Mol. Cel. Endocrinol. 2010. Vol. 316, N 2. P. 129–139. DOI: 10.1016/j.mce.2009.08.018Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ // Mol. Cel. Endocrinol. 2010. Vol. 316, N 2. P. 129–139. DOI: 10.1016/j.mce.2009.08.018Hausman G.J., Barb C.R., Lents C.A. Leptin and reproductive function // Biochimie. 2012. Vol. 94, N 10. P. 2075–2081. DOI: 10.1016/j.biochi.2012.02.022Hausman G.J., Barb C.R., Lents C.A. Leptin and reproductive function // Biochimie. 2012. Vol. 94, N 10. P. 2075–2081. DOI: 10.1016/j.biochi.2012.02.022Sweeney G. Cardiovascular effects of leptin // Nat. Rev. Cardiol. 2009. Vol. 7, N 1. P. 22–29. DOI:10.1038/nrcardio.2009.224Sweeney G. Cardiovascular effects of leptin // Nat. Rev. Cardiol. 2009. Vol. 7, N 1. P. 22–29. DOI:10.1038/nrcardio.2009.224Singh M., Bedi U.S., Singh P.P., et al. Leptin and the clinical cardiovascular risk // Int. J. Cardiol. 2010. Vol. 140, N 3. P. 266–271. DOI: 10.1016/j.ijcard.2009.07.019Singh M., Bedi U.S., Singh P.P., et al. Leptin and the clinical cardiovascular risk // Int. J. Cardiol. 2010. Vol. 140, N 3. P. 266–271. DOI: 10.1016/j.ijcard.2009.07.019Sierra-Johnson J., Romero-Corral A., Lopez-Jimenez F., et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the united states population // The Am. J. Cardiol. 2007. Vol. 100, N 2. P. 234–239. DOI: 10.1016/j.amjcard.2007.02.088Sierra-Johnson J., Romero-Corral A., Lopez-Jimenez F., et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the united states population // The Am. J. Cardiol. 2007. Vol. 100, N 2. P. 234–239. DOI: 10.1016/j.amjcard.2007.02.088Momin A.U., Melikian N., Shah A.M., et al. Leptin is an endothelial independent vasodilator in humans with coronaryartery disease: evidence for tissue specificity of leptin resistance // Eur. Heart J. 2006. Vol. 27. P. 2294–2299. DOI:10.1093/eurheartj/ehi831.Momin A.U., Melikian N., Shah A.M., et al. Leptin is an endothelial independent vasodilator in humans with coronaryartery disease: evidence for tissue specificity of leptin resistance // Eur. Heart J. 2006. Vol. 27. P. 2294–2299. DOI:10.1093/eurheartj/ehi831.Wolk R., Deb A., Caplice N.M., et al. Leptin receptor and functional effects of leptin in human endothelial progenitor cells // Atherosclerosis. 2005. Vol. 183. P. 131–139. DOI: 10.1016/j.atherosclerosis.2005.03.048Wolk R., Deb A., Caplice N.M., et al. Leptin receptor and functional effects of leptin in human endothelial progenitor cells // Atherosclerosis. 2005. Vol. 183. P. 131–139. DOI: 10.1016/j.atherosclerosis.2005.03.048Kappelle P.J.W. H., Dullaart R.P.F., van Beek A.P., et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case–control study // Eur. J. Int. Med. 2012. Vol. 23, N 8. P. 755–759. DOI: 10.1016/j.ejim.2012.06.013Kappelle P.J.W. H., Dullaart R.P.F., van Beek A.P., et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case–control study // Eur. J. Int. Med. 2012. Vol. 23, N 8. P. 755–759. DOI: 10.1016/j.ejim.2012.06.013Zhu W., Cheng K.K., Vanhoutte P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). 2008. Vol. 114. P. 361–374. DOI: 10.1042/CS20070347Zhu W., Cheng K.K., Vanhoutte P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). 2008. Vol. 114. P. 361–374. DOI: 10.1042/CS20070347Lara-Castro C., Luo N., Wallace P., et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster // Diabetes. 2006. Vol. 55, N 1. P. 249– 259. DOI: 10.2337/diabetes.55.01.06.db05-1105Lara-Castro C., Luo N., Wallace P., et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster // Diabetes. 2006. Vol. 55, N 1. P. 249– 259. DOI: 10.2337/diabetes.55.01.06.db05-1105Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany // J. Am. Coll. Cardiol. 2006. Vol. 48. P. 1369–1377. DOI: 10.1016/j.jacc.2006.06.053Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany // J. Am. Coll. Cardiol. 2006. Vol. 48. P. 1369–1377. DOI: 10.1016/j.jacc.2006.06.053Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 571–576. DOI: 10.1210/jc.2006-1067Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 571–576. DOI: 10.1210/jc.2006-1067Torigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men // Clin. Endocrinol. (Oxf). 2007. Vol. 67. P. 276–281. DOI:10.1111/j.1365-2265.2007.02876.xTorigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men // Clin. Endocrinol. (Oxf). 2007. Vol. 67. P. 276–281. DOI:10.1111/j.1365-2265.2007.02876.xPilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4792–4796. DOI:10.1210/jc.2005-0167Pilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4792–4796. DOI:10.1210/jc.2005-0167Lo J., Dolan S.E., Kanter J.R., et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 1677–1682. DOI: 10.1210/jc.2005-2775Lo J., Dolan S.E., Kanter J.R., et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 1677–1682. DOI: 10.1210/jc.2005-2775Nilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 2758– 2762. DOI: 10.1161/01.ATV.0000249638.01416.4bNilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 2758– 2762. DOI: 10.1161/01.ATV.0000249638.01416.4bNorata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery // Stroke. 2007. Vol. 38. P. 2844–2846. DOI: 10.1161/STROKEAHA.107.485540Norata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery // Stroke. 2007. Vol. 38. P. 2844–2846. DOI: 10.1161/STROKEAHA.107.485540Kotani K., Shimohiro H., Sakane N. The relationship between leptin: adiponectin ratio and carotid intimamedia thickness in asymptomatic females // Stroke. 2008. Vol. 39. P. e32–e33. DOI:10.1161/STROKEAHA.107.505669Kotani K., Shimohiro H., Sakane N. The relationship between leptin: adiponectin ratio and carotid intimamedia thickness in asymptomatic females // Stroke. 2008. Vol. 39. P. e32–e33. DOI:10.1161/STROKEAHA.107.505669Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness // Diabetologia. 2005. Vol. 48. P. 2684–2686. DOI:10.1007/s00125-005-0015-4Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness // Diabetologia. 2005. Vol. 48. P. 2684–2686. DOI:10.1007/s00125-005-0015-4Mitsuhashi H., Yatsuya H., Tamakoshi K., et al. Adiponectin level and left ventricular hypertrophy in Japanese men // Hypertension. 2007. Vol. 49. P. 1448–1454. DOI: 10.1161/HYPERTENSIONAHA.106.079509Mitsuhashi H., Yatsuya H., Tamakoshi K., et al. Adiponectin level and left ventricular hypertrophy in Japanese men // Hypertension. 2007. Vol. 49. P. 1448–1454. DOI: 10.1161/HYPERTENSIONAHA.106.079509progenitor cells // Atherosclerosis. 2005. Vol. 183. P. 131–139. DOI: 10.1016/j.atherosclerosis.2005.03.048progenitor cells // Atherosclerosis. 2005. Vol. 183. P. 131–139. DOI: 10.1016/j.atherosclerosis.2005.03.048Kappelle P.J.W. H., Dullaart R.P.F., van Beek A.P., et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case–control study // Eur. J. Int. Med. 2012. Vol. 23, N 8. P. 755–759. DOI: 10.1016/j.ejim.2012.06.013Kappelle P.J.W. H., Dullaart R.P.F., van Beek A.P., et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case–control study // Eur. J. Int. Med. 2012. Vol. 23, N 8. P. 755–759. DOI: 10.1016/j.ejim.2012.06.013Zhu W., Cheng K.K., Vanhoutte P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). 2008. Vol. 114. P. 361–374. DOI: 10.1042/CS20070347Zhu W., Cheng K.K., Vanhoutte P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). 2008. Vol. 114. P. 361–374. DOI: 10.1042/CS20070347Lara-Castro C., Luo N., Wallace P., et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster // Diabetes. 2006. Vol. 55, N 1. P. 249– 259. DOI: 10.2337/diabetes.55.01.06.db05-1105Lara-Castro C., Luo N., Wallace P., et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster // Diabetes. 2006. Vol. 55, N 1. P. 249– 259. DOI: 10.2337/diabetes.55.01.06.db05-1105Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany // J. Am. Coll. Cardiol. 2006. Vol. 48. P. 1369–1377. DOI: 10.1016/j.jacc.2006.06.053Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany // J. Am. Coll. Cardiol. 2006. Vol. 48. P. 1369–1377. DOI: 10.1016/j.jacc.2006.06.053Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 571–576. DOI: 10.1210/jc.2006-1067Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 571–576. DOI: 10.1210/jc.2006-1067Torigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men // Clin. Endocrinol. (Oxf). 2007. Vol. 67. P. 276–281. DOI:10.1111/j.1365-2265.2007.02876.xTorigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men // Clin. Endocrinol. (Oxf). 2007. Vol. 67. P. 276–281. DOI:10.1111/j.1365-2265.2007.02876.xPilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4792–4796. DOI:10.1210/jc.2005-0167Pilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4792–4796. DOI:10.1210/jc.2005-0167Lo J., Dolan S.E., Kanter J.R., et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 1677–1682. DOI: 10.1210/jc.2005-2775Lo J., Dolan S.E., Kanter J.R., et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 1677–1682. DOI: 10.1210/jc.2005-2775Nilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 2758– 2762. DOI: 10.1161/01.ATV.0000249638.01416.4bNilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 2758– 2762. DOI: 10.1161/01.ATV.0000249638.01416.4bNorata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery // Stroke. 2007. Vol. 38. P. 2844–2846. DOI: 10.1161/STROKEAHA.107.485540Norata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery // Stroke. 2007. Vol. 38. P. 2844–2846. DOI: 10.1161/STROKEAHA.107.485540Kotani K., Shimohiro H., Sakane N. The relationship between leptin: adiponectin ratio and carotid intimamedia thickness in asymptomatic females // Stroke. 2008. Vol. 39. P. e32–e33. DOI:10.1161/STROKEAHA.107.505669Kotani K., Shimohiro H., Sakane N. The relationship between leptin: adiponectin ratio and carotid intimamedia thickness in asymptomatic females // Stroke. 2008. Vol. 39. P. e32–e33. DOI:10.1161/STROKEAHA.107.505669Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness // Diabetologia. 2005. Vol. 48. P. 2684–2686. DOI:10.1007/s00125-005-0015-4Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness // Diabetologia. 2005. Vol. 48. P. 2684–2686. DOI:10.1007/s00125-005-0015-4Mitsuhashi H., Yatsuya H., Tamakoshi K., et al. Adiponectin level and left ventricular hypertrophy in Japanese men // Hypertension. 2007. Vol. 49. P. 1448–1454. DOI: 10.1161/HYPERTENSIONAHA.106.079509Mitsuhashi H., Yatsuya H., Tamakoshi K., et al. Adiponectin level and left ventricular hypertrophy in Japanese men // Hypertension. 2007. Vol. 49. P. 1448–1454. DOI: 10.1161/HYPERTENSIONAHA.106.079509progenitor cells // Atherosclerosis. 2005. Vol. 183. P. 131–139. DOI: 10.1016/j.atherosclerosis.2005.03.048progenitor cells // Atherosclerosis. 2005. Vol. 183. P. 131–139. DOI: 10.1016/j.atherosclerosis.2005.03.048Kappelle P.J.W. H., Dullaart R.P.F., van Beek A.P., et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case–control study // Eur. J. Int. Med. 2012. Vol. 23, N 8. P. 755–759. DOI: 10.1016/j.ejim.2012.06.013Kappelle P.J.W. H., Dullaart R.P.F., van Beek A.P., et al. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case–control study // Eur. J. Int. Med. 2012. Vol. 23, N 8. P. 755–759. DOI: 10.1016/j.ejim.2012.06.013Zhu W., Cheng K.K., Vanhoutte P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). 2008. Vol. 114. P. 361–374. DOI: 10.1042/CS20070347Zhu W., Cheng K.K., Vanhoutte P.M., et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond). 2008. Vol. 114. P. 361–374. DOI: 10.1042/CS20070347Lara-Castro C., Luo N., Wallace P., et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster // Diabetes. 2006. Vol. 55, N 1. P. 249– 259. DOI: 10.2337/diabetes.55.01.06.db05-1105Lara-Castro C., Luo N., Wallace P., et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster // Diabetes. 2006. Vol. 55, N 1. P. 249– 259. DOI: 10.2337/diabetes.55.01.06.db05-1105Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany // J. Am. Coll. Cardiol. 2006. Vol. 48. P. 1369–1377. DOI: 10.1016/j.jacc.2006.06.053Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany // J. Am. Coll. Cardiol. 2006. Vol. 48. P. 1369–1377. DOI: 10.1016/j.jacc.2006.06.053Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 571–576. DOI: 10.1210/jc.2006-1067Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 571–576. DOI: 10.1210/jc.2006-1067Torigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men // Clin. Endocrinol. (Oxf). 2007. Vol. 67. P. 276–281. DOI:10.1111/j.1365-2265.2007.02876.xTorigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men // Clin. Endocrinol. (Oxf). 2007. Vol. 67. P. 276–281. DOI:10.1111/j.1365-2265.2007.02876.xPilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4792–4796. DOI:10.1210/jc.2005-0167Pilz S., Horejsi R., Moller R., et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4792–4796. DOI:10.1210/jc.2005-0167Lo J., Dolan S.E., Kanter J.R., et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 1677–1682. DOI: 10.1210/jc.2005-2775Lo J., Dolan S.E., Kanter J.R., et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 1677–1682. DOI: 10.1210/jc.2005-2775Nilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 2758– 2762. DOI: 10.1161/01.ATV.0000249638.01416.4bNilsson P.M., Engstrom G., Hedblad B., et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 2758– 2762. DOI: 10.1161/01.ATV.0000249638.01416.4bNorata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery // Stroke. 2007. Vol. 38. P. 2844–2846. DOI: 10.1161/STROKEAHA.107.485540Norata G.D., Raselli S., Grigore L., et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery // Stroke. 2007. Vol. 38. P. 2844–2846. DOI: 10.1161/STROKEAHA.107.485540Kotani K., Shimohiro H., Sakane N. The relationship between leptin: adiponectin ratio and carotid intimamedia thickness in asymptomatic females // Stroke. 2008. Vol. 39. P. e32–e33. DOI:10.1161/STROKEAHA.107.505669Kotani K., Shimohiro H., Sakane N. The relationship between leptin: adiponectin ratio and carotid intimamedia thickness in asymptomatic females // Stroke. 2008. Vol. 39. P. e32–e33. DOI:10.1161/STROKEAHA.107.505669Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness // Diabetologia. 2005. Vol. 48. P. 2684–2686. DOI:10.1007/s00125-005-0015-4Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness // Diabetologia. 2005. Vol. 48. P. 2684–2686. DOI:10.1007/s00125-005-0015-4Mitsuhashi H., Yatsuya H., Tamakoshi K., et al. Adiponectin level and left ventricular hypertrophy in Japanese men // Hypertension. 2007. Vol. 49. P. 1448–1454. DOI: 10.1161/HYPERTENSIONAHA.106.079509Mitsuhashi H., Yatsuya H., Tamakoshi K., et al. Adiponectin level and left ventricular hypertrophy in Japanese men // Hypertension. 2007. Vol. 49. P. 1448–1454. DOI: 10.1161/HYPERTENSIONAHA.106.079509Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases // Blood. 2011. Vol. 117. P. 3720–3732. DOI: 10.1182/blood-2010-07-273417Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases // Blood. 2011. Vol. 117. P. 3720–3732. DOI: 10.1182/blood-2010-07-273417Dinarello C.A, Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases // Nat. Rev. Drug. Discov. 2012. Vol. 11. P. 633–652. DOI:10.1038/nrd3800Dinarello C.A, Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases // Nat. Rev. Drug. Discov. 2012. Vol. 11. P. 633–652. DOI:10.1038/nrd3800March C.J., Mosley B., Larsen A., et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs // Nature. 1985. Vol. 315, N 6021. P. 641–647. DOI: 10.1038/315641a0March C.J., Mosley B., Larsen A., et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs // Nature. 1985. Vol. 315, N 6021. P. 641–647. DOI: 10.1038/315641a0Auron P.E., Webb A.C., Rosenwasser L.J., et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA // Proc. Nat. Acad. Sci. U. S. A. 1984. Vol. 81, N 24. P. 7907–7911. DOI: 10.1073/pnas.81.24.7907Auron P.E., Webb A.C., Rosenwasser L.J., et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA // Proc. Nat. Acad. Sci. U. S. A. 1984. Vol. 81, N 24. P. 7907–7911. DOI: 10.1073/pnas.81.24.7907Terkeltaub R., Sundy J.S., Schumacher H.R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study // Ann. Rheum. Dis. 2009. Vol. 68. P. 1613–1617. DOI: 10.1136/ard.2009.108936Terkeltaub R., Sundy J.S., Schumacher H.R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study // Ann. Rheum. Dis. 2009. Vol. 68. P. 1613–1617. DOI: 10.1136/ard.2009.108936Lamkanfi M., Kanneganti T.D. Nlrp3: an immune sensor of cellular stress and infection // Int. J. Biochem. Cell. Biol. 2010. Vol. 42, N 6. P. 792–795. DOI: 10.1016/j.biocel.2010.01.008Lamkanfi M., Kanneganti T.D. Nlrp3: an immune sensor of cellular stress and infection // Int. J. Biochem. Cell. Biol. 2010. Vol. 42, N 6. P. 792–795. DOI: 10.1016/j.biocel.2010.01.008Ковалева Ю.В. Гормоны жировой ткани и их роль в формировании гормонального статуса и патогенезе метаболических нарушений у женщин // Артериальная гипертензия. 2015. Т. 21, № 4. С. 356– 370. DOI: 10.18705/1607-419X-2015-21-4-356-370Ковалева Ю.В. Гормоны жировой ткани и их роль в формировании гормонального статуса и патогенезе метаболических нарушений у женщин // Артериальная гипертензия. 2015. Т. 21, № 4. С. 356– 370. DOI: 10.18705/1607-419X-2015-21-4-356-370Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways // Physiol. Rev. 2006. Vol. 86, N 2. P. 515–581. DOI: 10.1152/physrev.00024.2005Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways // Physiol. Rev. 2006. Vol. 86, N 2. P. 515–581. DOI: 10.1152/physrev.00024.2005Scheller J., Chalaris A., Schmidt-Arras D., RoseJohn S. The proand anti-inflammatory properties of the cytokine interleukin-6 // Biochim. Biophys. Acta. 2011. Vol. 1813, N 5. P. 878–888. DOI: 10.1016/j.bbamcr.2011.01.034Scheller J., Chalaris A., Schmidt-Arras D., RoseJohn S. The proand anti-inflammatory properties of the cytokine interleukin-6 // Biochim. Biophys. Acta. 2011. Vol. 1813, N 5. P. 878–888. DOI: 10.1016/j.bbamcr.2011.01.034Libby P., Rocha V.Z. All roads lead to IL-6: a central hub of cardiometabolic signaling // Int. J. Cardiol. 2018. Vol. 259. P. 213–215. DOI: 10.1016/j.ijcard.2018.02.062Libby P., Rocha V.Z. All roads lead to IL-6: a central hub of cardiometabolic signaling // Int. J. Cardiol. 2018. Vol. 259. P. 213–215. DOI: 10.1016/j.ijcard.2018.02.062Huber S.A., Sakkinen P., Conze D., et al. Interleukin-6 exacerbates early atherosclerosis in mice // Arterioscler. Thromb. Vasc. Biol. 1999. Vol. 19, N 10. P. 2364–2367. DOI: 10.1161/01.atv.19.10.2364Huber S.A., Sakkinen P., Conze D., et al. Interleukin-6 exacerbates early atherosclerosis in mice // Arterioscler. Thromb. Vasc. Biol. 1999. Vol. 19, N 10. P. 2364–2367. DOI: 10.1161/01.atv.19.10.2364Schieffer B., Selle T., Hilfiker A., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis // Circulation. 2004. Vol. 110. P. 3493–3500. DOI: 10.1161/01.CIR.0000148135.08582.97Schieffer B., Selle T., Hilfiker A., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis // Circulation. 2004. Vol. 110. P. 3493–3500. DOI: 10.1161/01.CIR.0000148135.08582.97Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow D.I., Holmes M.V., et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis // Lancet. 2012. Vol. 379, N 9822. P. 1214–1224. DOI: 10.1016/S0140-6736(12)60110-XInterleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow D.I., Holmes M.V., et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis // Lancet. 2012. Vol. 379, N 9822. P. 1214–1224. DOI: 10.1016/S0140-6736(12)60110-XRemick G.D. Interleukin-8 // Crit. Care. Med. 2005. Vol. 33, N 12. P. s646–s647. DOI: 10.1097/01.ccm.0000186783.34908.18Remick G.D. Interleukin-8 // Crit. Care. Med. 2005. Vol. 33, N 12. P. s646–s647. DOI: 10.1097/01.ccm.0000186783.34908.18Waugh J.J.D., Wilson C. The interleukin-8 pathway in cancer // Clin. Cancer. Res. 2008. Vol. 14, N 21. P. 6735–6741. DOI: 10.1158/1078-0432.CCR-07-4843Waugh J.J.D., Wilson C. The interleukin-8 pathway in cancer // Clin. Cancer. Res. 2008. Vol. 14, N 21. P. 6735–6741. DOI: 10.1158/1078-0432.CCR-07-4843Gimbrone M.A. Jr., Obin M.S., Brock A.F., et al. Endothelial interleukin-8: a novel inhibitor of leukocyte endothelia linteractions // Science. 1989. Vol. 246, N 4937. P. 1601–1603. DOI: 10.1126/science.2688092Gimbrone M.A. Jr., Obin M.S., Brock A.F., et al. Endothelial interleukin-8: a novel inhibitor of leukocyte endothelia linteractions // Science. 1989. Vol. 246, N 4937. P. 1601–1603. DOI: 10.1126/science.2688092DeForge L.E., Preston A.M., Takeuchi E., et al. Regulation of interleukin 8 gene expression by oxidant stress // J. Biol. Chem. 1993. Vol. 268, N 34. P. 25568–25576. PMID: 8244994DeForge L.E., Preston A.M., Takeuchi E., et al. Regulation of interleukin 8 gene expression by oxidant stress // J. Biol. Chem. 1993. Vol. 268, N 34. P. 25568–25576. PMID: 8244994Inoue T., Komoda H., Nonaka M., et al. Interleukin8as an independent predictor of long-term clinical outcome in patients with coronary artery disease // Int. J. Cardiol. 2008. Vol. 124. P. 319–325. DOI: 10.1016/j.ijcard.2007.02.012Inoue T., Komoda H., Nonaka M., et al. Interleukin8as an independent predictor of long-term clinical outcome in patients with coronary artery disease // Int. J. Cardiol. 2008. Vol. 124. P. 319–325. DOI: 10.1016/j.ijcard.2007.02.012Panichi V., Taccola D., Rizza G.M., et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardio-vascular mortality in dialytic patients // Nephron. Clin. Pract. 2006. Vol. 102, N 2. P. 51–58. DOI: 10.1159/000088923Panichi V., Taccola D., Rizza G.M., et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardio-vascular mortality in dialytic patients // Nephron. Clin. Pract. 2006. Vol. 102, N 2. P. 51–58. DOI: 10.1159/000088923Herder C., Baumert J., Thorand B., et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984– 2002 // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26, N 9. P. 2147–2152. DOI: 10.1161/01.ATV.0000235691.84430.86Herder C., Baumert J., Thorand B., et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984– 2002 // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26, N 9. P. 2147–2152. DOI: 10.1161/01.ATV.0000235691.84430.86Wu Z.K., Laurikka J., Vikman S., et al. High postoperative interleukin-8 levels related to atrial fibrillation in patients undergoing coronary artery bypass surgery // World J. Surg. 2008. Vol. 32, N 12. P. 2643–2649. DOI: 10.1007/s00268-008-9758-7Wu Z.K., Laurikka J., Vikman S., et al. High postoperative interleukin-8 levels related to atrial fibrillation in patients undergoing coronary artery bypass surgery // World J. Surg. 2008. Vol. 32, N 12. P. 2643–2649. DOI: 10.1007/s00268-008-9758-7Nandate K., Vuylsteke A., Crosbie A.E., et al. Cerebrovascular cytokine responses during coronary artery bypass surgery: specific production of interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass // Anesth. Analg. 1999. Vol. 89, N 4. P. 823–828. DOI: 10.1097/00000539-199910000-00003Nandate K., Vuylsteke A., Crosbie A.E., et al. Cerebrovascular cytokine responses during coronary artery bypass surgery: specific production of interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass // Anesth. Analg. 1999. Vol. 89, N 4. P. 823–828. DOI: 10.1097/00000539-199910000-00003Kim C.S., Park H.S., Kawada T., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters // Int. J. Obes. (Lond). 2006. Vol. 30, N 9. P. 1347–1355. DOI: 10.1038/sj.ijo.0803259Kim C.S., Park H.S., Kawada T., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters // Int. J. Obes. (Lond). 2006. Vol. 30, N 9. P. 1347–1355. DOI: 10.1038/sj.ijo.0803259Fiorentino D.F., Bond M.W., Mosmann T. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones // J. Exp. Med. 1989. Vol. 170, N 6. P. 2081–2095. DOI: 10.1084/jem.170.6.2081Fiorentino D.F., Bond M.W., Mosmann T. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones // J. Exp. Med. 1989. Vol. 170, N 6. P. 2081–2095. DOI: 10.1084/jem.170.6.2081Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine // Immunol. Rev. 2008. Vol. 226. P. 205–218. DOI: 10.1111/j.1600-065X.2008.00706.xMosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine // Immunol. Rev. 2008. Vol. 226. P. 205–218. DOI: 10.1111/j.1600-065X.2008.00706.xSikka G., Miller K.L., Steppan J., et al. Interleukin 10 knockout frail mice develop cardiac and vascular dysfunction with increased age // Exp. Gerontol. 2013. Vol. 48, N 2. P. 128–135. DOI: 10.1016/j.exger.2012.11.001Sikka G., Miller K.L., Steppan J., et al. Interleukin 10 knockout frail mice develop cardiac and vascular dysfunction with increased age // Exp. Gerontol. 2013. Vol. 48, N 2. P. 128–135. DOI: 10.1016/j.exger.2012.11.001Didion S.P., Kinzenbaw D.A., Schrader L.I., et al. Endogenous interleukin-10 inhibits angiotensin ii–induced vascular dysfunction // Hypertension. 2009. Vol. 54. P. 619–624. DOI: 10.1161/HYPERTENSIONAHA.109.137158Didion S.P., Kinzenbaw D.A., Schrader L.I., et al. Endogenous interleukin-10 inhibits angiotensin ii–induced vascular dysfunction // Hypertension. 2009. Vol. 54. P. 619–624. DOI: 10.1161/HYPERTENSIONAHA.109.137158Malarstig A., Eriksson P., Hamsten A., et al. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome // Heart. 2008. Vol. 94. P. 724– 729. DOI: 10.1136/hrt.2007.119271Malarstig A., Eriksson P., Hamsten A., et al. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome // Heart. 2008. Vol. 94. P. 724– 729. DOI: 10.1136/hrt.2007.119271Cavusoglu E., Marmur J.D., Hojjati M.R., et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome // The Am. J. Med. 2011. Vol. 124, N 8. P. 724–730. DOI: 10.1016/j.amjmed.2011.02.040Cavusoglu E., Marmur J.D., Hojjati M.R., et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome // The Am. J. Med. 2011. Vol. 124, N 8. P. 724–730. DOI: 10.1016/j.amjmed.2011.02.040Izumi T., Nishii M. Diagnostic and prognostic biomarkers in acute myocarditis. Interleukin-10 // Herz. 2012. Vol. 37, N 6. P. 627–631. DOI: 10.1007/s00059012-3661-6Izumi T., Nishii M. Diagnostic and prognostic biomarkers in acute myocarditis. Interleukin-10 // Herz. 2012. Vol. 37, N 6. P. 627–631. DOI: 10.1007/s00059012-3661-6Santoro F., Tarantino N., Ferraretti A., et al. Serum interleukin 6 and 10 levels in Takotsubo cardiomyopathy: increased admission levels may predict adverse events at follow-up // Atherosclerosis. 2016. Vol. 254. P. 28–34. DOI: 10.1016/j.atherosclerosis.2016.09.012Santoro F., Tarantino N., Ferraretti A., et al. Serum interleukin 6 and 10 levels in Takotsubo cardiomyopathy: increased admission levels may predict adverse events at follow-up // Atherosclerosis. 2016. Vol. 254. P. 28–34. DOI: 10.1016/j.atherosclerosis.2016.09.012Maier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid a but decreased C-reactive protein // Circulation. 2005. Vol. 111, N 11. P. 1355–1361. DOI: 10.1161/01.CIR.0000158479.58589.0AMaier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid a but decreased C-reactive protein // Circulation. 2005. Vol. 111, N 11. P. 1355–1361. DOI: 10.1161/01.CIR.0000158479.58589.0AMalarstig A., Tenno T., Johnston N., et al. Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 2667–2672. DOI: 10.1161/01.ATV.0000191637.48129.9bMalarstig A., Tenno T., Johnston N., et al. Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 2667–2672. DOI: 10.1161/01.ATV.0000191637.48129.9bLee K.W., Blann A.D., Lip G.Y. Plasma markers of endothelial damage/ dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes // Thrombosis and Haemostasis. 2005. Vol. 94, N 5. P. 1077–1083. DOI: 10.1160/TH05-03-0179Lee K.W., Blann A.D., Lip G.Y. Plasma markers of endothelial damage/ dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes // Thrombosis and Haemostasis. 2005. Vol. 94, N 5. P. 1077–1083. DOI: 10.1160/TH05-03-0179Mead J.R., Irvine S.A., Ramji D.P. Lipoprotein lipase: structure, function, regulation, and role in disease // J. Mol. Med. 2002. Vol. 80, N 12. P. 753–769. DOI: 10.1007/s00109-002-0384-9Mead J.R., Irvine S.A., Ramji D.P. Lipoprotein lipase: structure, function, regulation, and role in disease // J. Mol. Med. 2002. Vol. 80, N 12. P. 753–769. DOI: 10.1007/s00109-002-0384-9Khera A.V., Won H., Peloso G.M., et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease // JAMA. 2017. Vol. 317, N 9. P. 937–946. DOI:10.1001/jama.2017.0972Khera A.V., Won H., Peloso G.M., et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease // JAMA. 2017. Vol. 317, N 9. P. 937–946. DOI:10.1001/jama.2017.0972Lotta L.A., Stewart I.D., Sharp S.J., et al. Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol– lowering alleles with risk of coronary disease and type 2 diabetes // JAMA Cardiol. 2018. Vol. 3, N 10. P. 957–966. DOI: 10.1001/jamacardio.2018.2866Lotta L.A., Stewart I.D., Sharp S.J., et al. Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol– lowering alleles with risk of coronary disease and type 2 diabetes // JAMA Cardiol. 2018. Vol. 3, N 10. P. 957–966. DOI: 10.1001/jamacardio.2018.2866Saika Y., Sakai N., Takahashi M. Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis // Eur. J. Clin. Invest. 2003. Vol. 33, N 3. P. 216–222. DOI: 10.1046/j.1365-2362.2003. 01129.xSaika Y., Sakai N., Takahashi M. Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis // Eur. J. Clin. Invest. 2003. Vol. 33, N 3. P. 216–222. DOI: 10.1046/j.1365-2362.2003. 01129.xHu Y., Liu W., Huang R. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases // J. Lipid. Res. 2006. Vol. 47, N 9. P. 1908–1914. DOI: 10.1194/jlr.M600108-JLR200Hu Y., Liu W., Huang R. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases // J. Lipid. Res. 2006. Vol. 47, N 9. P. 1908–1914. DOI: 10.1194/jlr.M600108-JLR200Sagoo G.S., Tatt I., Salanti G. Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: aHuGE association review and metaanalysis // Am. J. Epidemiol. 2008. Vol. 168, N 11. P. 1233–1246. DOI: 10.1093/aje/kwn235.Sagoo G.S., Tatt I., Salanti G. Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: aHuGE association review and metaanalysis // Am. J. Epidemiol. 2008. Vol. 168, N 11. P. 1233–1246. DOI: 10.1093/aje/kwn235.Xie L., Li Y.M. Lipoprotein lipase (LPL) polymorphism and the risk of coronary artery disease: a metaanalysis // Int. J. Environ. Res. Public. Health. 2017. Vol. 14, N 1. P. 84. DOI: 10.3390/ijerph14010084.Xie L., Li Y.M. Lipoprotein lipase (LPL) polymorphism and the risk of coronary artery disease: a metaanalysis // Int. J. Environ. Res. Public. Health. 2017. Vol. 14, N 1. P. 84. DOI: 10.3390/ijerph14010084.Jiang L., Zhong J., Dou X., et al. Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury // Neuroscience. 2015. Vol. 301. P. 375–383. DOI: 10.1016/j.neuroscience.2015Jiang L., Zhong J., Dou X., et al. Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury // Neuroscience. 2015. Vol. 301. P. 375–383. DOI: 10.1016/j.neuroscience.2015Rasmussen K.L., Tybjaerg-Hansen A., Nordestgaard B.G., et al. Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population // Atherosclerosis. 2016. Vol. 246. P. 63–70. DOI: 10.1016/j.atherosclerosis.2015.12.038Rasmussen K.L., Tybjaerg-Hansen A., Nordestgaard B.G., et al. Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population // Atherosclerosis. 2016. Vol. 246. P. 63–70. DOI: 10.1016/j.atherosclerosis.2015.12.038Sofat R., Cooper J.A., Kumari M., et al. Circulating apolipoprotein Econcentration and cardiovascular disease risk: meta-analysis of results from three studies // PLoS Med. 2016. Vol. 13, N 10. P. e1002146. DOI: 10.1371/journal.pmed.1002146Sofat R., Cooper J.A., Kumari M., et al. Circulating apolipoprotein Econcentration and cardiovascular disease risk: meta-analysis of results from three studies // PLoS Med. 2016. Vol. 13, N 10. P. e1002146. DOI: 10.1371/journal.pmed.1002146Corsetti J.P., Gansevoort R.T., Bakker S.J., et al. Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein // Metabolism. 2012. Vol. 61, N 7. P. 996–1002. DOI: 10.1016/j.metabol.2011.11.010Corsetti J.P., Gansevoort R.T., Bakker S.J., et al. Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein // Metabolism. 2012. Vol. 61, N 7. P. 996–1002. DOI: 10.1016/j.metabol.2011.11.010Mooijaart S.P., Berbee J.F., van Heemst D., et al. ApoE plasma levels and risk of cardiovascular mortality in old age // PLoS Med. 2006. Vol. 3, N 6. P. e176. DOI: 10.1371/journal.pmed.0030176Mooijaart S.P., Berbee J.F., van Heemst D., et al. ApoE plasma levels and risk of cardiovascular mortality in old age // PLoS Med. 2006. Vol. 3, N 6. P. e176. DOI: 10.1371/journal.pmed.0030176Huber-Lang M., Sarma J.V., Zetoune F.S., et al. Generation of C5a in the absence of C3: a new complement activation pathway // Nat. Med. 2006. Vol. 12, N 6. P. 682–687. DOI: 10.1038/nm1419Huber-Lang M., Sarma J.V., Zetoune F.S., et al. Generation of C5a in the absence of C3: a new complement activation pathway // Nat. Med. 2006. Vol. 12, N 6. P. 682–687. DOI: 10.1038/nm1419Barratt-Due A., Pischke S.E., Brekke O.L., et al. Bride and groom in systemic inflammation – the bells ring for complement and Toll in cooperation // Immunobiology. 2012. Vol. 217, N 11. P. 1047– 1056. DOI: 10.1016/j.imbio.2012.07.019Barratt-Due A., Pischke S.E., Brekke O.L., et al. Bride and groom in systemic inflammation – the bells ring for complement and Toll in cooperation // Immunobiology. 2012. Vol. 217, N 11. P. 1047– 1056. DOI: 10.1016/j.imbio.2012.07.019Busche M.N., Pavlov V., Takahashi K., et al. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-20binding lectin // Am. J. Physiol. Heart and Circ. Physiol. 2009. Vol. 297, N 5. P. H1853–H1859. DOI: 10.1152/ajpheart.00049.2009Busche M.N., Pavlov V., Takahashi K., et al. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-20binding lectin // Am. J. Physiol. Heart and Circ. Physiol. 2009. Vol. 297, N 5. P. H1853–H1859. DOI: 10.1152/ajpheart.00049.2009Trendelenburg M., Theroux P., Stebbins A., et al. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention // Eur. Heart J. 2010. Vol. 31, N 10. P. 1181–1187. DOI: 10.1093/eurheartj/ehp597Trendelenburg M., Theroux P., Stebbins A., et al. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention // Eur. Heart J. 2010. Vol. 31, N 10. P. 1181–1187. DOI: 10.1093/eurheartj/ehp597Zhang M., Hou Y.J., Cavusoglu E., et al. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans // Int. J. Cardiol. 2013. Vol. 166, N 2. P. 499–504. DOI: 10.1016/j.ijcard.2011.11.032Zhang M., Hou Y.J., Cavusoglu E., et al. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans // Int. J. Cardiol. 2013. Vol. 166, N 2. P. 499–504. DOI: 10.1016/j.ijcard.2011.11.032Frauenknecht V., Thiel S., Storm L., et al. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio-and cerebrovascular diseases // Clin. Experim. Immunol. 2013. Vol. 173, N 1. P. 112– 120. DOI: 10.1111/cei.12093Frauenknecht V., Thiel S., Storm L., et al. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio-and cerebrovascular diseases // Clin. Experim. Immunol. 2013. Vol. 173, N 1. P. 112– 120. DOI: 10.1111/cei.12093Palikhe A., Sinisalo J., Seppänen M., et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events // The Am. J. Cardiol. 2007. Vol. 99, N 7. P. 890–895. DOI: 10.1016/j.amjcard.2006.11.034Palikhe A., Sinisalo J., Seppänen M., et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events // The Am. J. Cardiol. 2007. Vol. 99, N 7. P. 890–895. DOI: 10.1016/j.amjcard.2006.11.034Engström G., Hedblad B., Janzon L., et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study // Eur. J. Cardiovasc. Prev. Rehabil. 2007. Vol. 14, N 3. P. 392–397. DOI: 10.1097/01.hjr.0000244582.30421.b2Engström G., Hedblad B., Janzon L., et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study // Eur. J. Cardiovasc. Prev. Rehabil. 2007. Vol. 14, N 3. P. 392–397. DOI: 10.1097/01.hjr.0000244582.30421.b2GombosT., Förhécz Z., Pozsonyi Z., et al. Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure // Clin. Res. Cardiol: Official Journal of the German Cardiac. Society. 2012. Vol. 101. N 8. P. 607–615. DOI: 10.1007/s00392-012-0432-6GombosT., Förhécz Z., Pozsonyi Z., et al. Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure // Clin. Res. Cardiol: Official Journal of the German Cardiac. Society. 2012. Vol. 101. N 8. P. 607–615. DOI: 10.1007/s00392-012-0432-6Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction // Lancet. 1987. Vol. 2, N 8549. P. 3–9. DOI: 10.1016/s0140-6736(87)93050-9Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction // Lancet. 1987. Vol. 2, N 8549. P. 3–9. DOI: 10.1016/s0140-6736(87)93050-9Yarmolinsky J., Bordin Barbieri N., Weinmann T., et al. Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies // Sci. Rep. 2016. Vol. 6. P. 17714. DOI: 10.1038/srep17714Yarmolinsky J., Bordin Barbieri N., Weinmann T., et al. Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies // Sci. Rep. 2016. Vol. 6. P. 17714. DOI: 10.1038/srep17714Smits M.M., Woudstra P., Utzschneider K.M., et al. Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis // Ann. Epidemiol. 2013. Vol. 23, N 7. P. 415– 421. DOI: 10.1016/j.annepidem.2013.03.001Smits M.M., Woudstra P., Utzschneider K.M., et al. Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis // Ann. Epidemiol. 2013. Vol. 23, N 7. P. 415– 421. DOI: 10.1016/j.annepidem.2013.03.001Tofler G.H., Massaro J., O’Donnell C.J., et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham Heart Study // Thromb. Res. 2016. Vol. 140. P. 30–35. DOI: 10.1016/j.thromres.2016.02.002Tofler G.H., Massaro J., O’Donnell C.J., et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham Heart Study // Thromb. Res. 2016. Vol. 140. P. 30–35. DOI: 10.1016/j.thromres.2016.02.002Meltzer M.E., Doggen C.J., de Groot P.G., et al. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men // Blood. 2010. Vol. 116. P. 529–536. DOI: 10.1182/blood-2010-01-263103Meltzer M.E., Doggen C.J., de Groot P.G., et al. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men // Blood. 2010. Vol. 116. P. 529–536. DOI: 10.1182/blood-2010-01-263103Thogersen A.M., Nilsson T.K., Weinehall L., et al. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years // Blood. Coagul. Fibrinolysis. 2009. Vol. 20, N 5. P. 340–346. DOI: 10.1097/MBC.0b013e32832a5fd1Thogersen A.M., Nilsson T.K., Weinehall L., et al. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years // Blood. Coagul. Fibrinolysis. 2009. Vol. 20, N 5. P. 340–346. DOI: 10.1097/MBC.0b013e32832a5fd1Smith A., Patterson C., Yarnell J., et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke // The Caerphilly Study Circulation. 2005. Vol. 112, N 20. P. 3080–3087. DOI: 10.1161/CIRCULATIONAHA.105.557132Smith A., Patterson C., Yarnell J., et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke // The Caerphilly Study Circulation. 2005. Vol. 112, N 20. P. 3080–3087. DOI: 10.1161/CIRCULATIONAHA.105.557132Knudsen A., Katzenstein T.L., Benfield T., et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals // AIDS. 2014. Vol. 28, N 8. P. 1171–1179. DOI: 10.1097/QAD.0000000000000247Knudsen A., Katzenstein T.L., Benfield T., et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals // AIDS. 2014. Vol. 28, N 8. P. 1171–1179. DOI: 10.1097/QAD.0000000000000247Brazionis L., Rowley K., Jenkins A., et al. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy // Arterioscler. Thromb. Vasc. Biol. 2008. Vol. 28, N 4. P. 786–791. DOI: 10.1161/ATVBAHA.107.160168Brazionis L., Rowley K., Jenkins A., et al. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy // Arterioscler. Thromb. Vasc. Biol. 2008. Vol. 28, N 4. P. 786–791. DOI: 10.1161/ATVBAHA.107.160168Sethi J.K., Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? // Trends Mol. Med. 2005. Vol. 11, N 8. P. 344–347. DOI: 10.1016/j.molmed.2005.06.010Sethi J.K., Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? // Trends Mol. Med. 2005. Vol. 11, N 8. P. 344–347. DOI: 10.1016/j.molmed.2005.06.010Yu F., Li J., Huang Q., et al. Increased peripheral blood visfatin concentrations may be a risk marker of coronary artery disease: a meta-analysis of observational studies // Angiology. 2018. Vol. 69, N 9. P. 825–834. DOI: 10.1177/0003319718771125Yu F., Li J., Huang Q., et al. Increased peripheral blood visfatin concentrations may be a risk marker of coronary artery disease: a meta-analysis of observational studies // Angiology. 2018. Vol. 69, N 9. P. 825–834. DOI: 10.1177/0003319718771125Auguet T., Aragonиs G., Guiu-Jurado E., et al. Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque // BMC Cardiovasc. Disord. 2016. Vol. 16, N 1. P. 149. DOI: 10.1186/s12872-016-0320-5Auguet T., Aragonиs G., Guiu-Jurado E., et al. Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque // BMC Cardiovasc. Disord. 2016. Vol. 16, N 1. P. 149. DOI: 10.1186/s12872-016-0320-5Zheng L.Y., Xu X., Wan R.H., et al. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes // Diabetol. Metab. Syndr. 2019. Vol. 11. P. 60. DOI: 10.1186/s13098-019-0455-5Zheng L.Y., Xu X., Wan R.H., et al. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes // Diabetol. Metab. Syndr. 2019. Vol. 11. P. 60. DOI: 10.1186/s13098-019-0455-5Goosens G.H., Blaak E.E., van Baak M.A. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesityrelated disorders // Obes. Rev. 2003. Vol. 4, N 1. P. 43–55. DOI: 10.1046/j.1467-789x.2003.00091.xGoosens G.H., Blaak E.E., van Baak M.A. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesityrelated disorders // Obes. Rev. 2003. Vol. 4, N 1. P. 43–55. DOI: 10.1046/j.1467-789x.2003.00091.xYvan-Charvet L., Massiera F., Lamande ́ N., et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue // Endocrinology. 2009. Vol. 150, N 3. P. 1421–1428. DOI: 10.1210/en.2008-1120Yvan-Charvet L., Massiera F., Lamande ́ N., et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue // Endocrinology. 2009. Vol. 150, N 3. P. 1421–1428. DOI: 10.1210/en.2008-1120LeMieuxM. J., Ramalingam L., Mynatt R.L., et al. Inactivation of adipose angiotensinogen reduces adipose tissue macrophages and increases metabolic activity // Obesity (Silver Spring). 2016. Vol. 24, N 2. P. 359–367. DOI: 10.1002/oby.21352LeMieuxM. J., Ramalingam L., Mynatt R.L., et al. Inactivation of adipose angiotensinogen reduces adipose tissue macrophages and increases metabolic activity // Obesity (Silver Spring). 2016. Vol. 24, N 2. P. 359–367. DOI: 10.1002/oby.21352Yiannikouris F., Gupte M., Putnam K., Thatcher S., et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice // Hypertension. 2012. Vol. 60, N 6. P. 1524–1530. DOI: 10.1161/hypertensionaha.112.192690Yiannikouris F., Gupte M., Putnam K., Thatcher S., et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice // Hypertension. 2012. Vol. 60, N 6. P. 1524–1530. DOI: 10.1161/hypertensionaha.112.192690Kouyama R., Suganami T., Nishida J., et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin ii type 1a receptor // Endocrinology. 2005. Vol. 146, N 8. P. 3481–3489. DOI: 10.1210/en.2005-0003Kouyama R., Suganami T., Nishida J., et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin ii type 1a receptor // Endocrinology. 2005. Vol. 146, N 8. P. 3481–3489. DOI: 10.1210/en.2005-0003Tatemoto K., Hosoya M., Habata Y., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor // Biochem. Biophys. Res. Commun. 1998. Vol. 251, N 2. P. 471–476. DOI: 10.1006/bbrc.1998.9489Tatemoto K., Hosoya M., Habata Y., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor // Biochem. Biophys. Res. Commun. 1998. Vol. 251, N 2. P. 471–476. DOI: 10.1006/bbrc.1998.9489Chandrasekaran B., Dar O., McDonagh T. The role of apelin in cardio-vascular function and heart failure // Eur. J. Heart. Fail. 2008. Vol. 10, N 8. P. 725–732. DOI: 10.1016/j.ejheart.2008.06.002Chandrasekaran B., Dar O., McDonagh T. The role of apelin in cardio-vascular function and heart failure // Eur. J. Heart. Fail. 2008. Vol. 10, N 8. P. 725–732. DOI: 10.1016/j.ejheart.2008.06.002Kidoya H., Ueno M., Yamada Y., et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis // EMBO J. 2008. Vol. 27, N 3. P. 522–534. DOI: 10.1038/sj.emboj.7601982Kidoya H., Ueno M., Yamada Y., et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis // EMBO J. 2008. Vol. 27, N 3. P. 522–534. DOI: 10.1038/sj.emboj.7601982Garcia-Diaz D., Campion J., Milagro F.I., et al. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers // Mol. Cell Biochem. 2007. Vol. 305, N 1-2. P. 87–94. DOI: 10.1007/s11010-007-9531-5Garcia-Diaz D., Campion J., Milagro F.I., et al. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers // Mol. Cell Biochem. 2007. Vol. 305, N 1-2. P. 87–94. DOI: 10.1007/s11010-007-9531-5Falcone C., Buzzi M.P., D’Angelo A., et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation // Int. J. Immunopathol. Pharmacol. 2010. Vol. 23, N 3. P. 917–925. DOI: 10.1177/039463201002300328Falcone C., Buzzi M.P., D’Angelo A., et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation // Int. J. Immunopathol. Pharmacol. 2010. Vol. 23, N 3. P. 917–925. DOI: 10.1177/039463201002300328Tycinska A.M., Sobkowicz B., Mroczko B., et al. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction // Clin. Chim. Acta. 2010. Vol. 411, N 23-24. P. 2014–2018. DOI: 10.1016/j.cca.2010.08.024Tycinska A.M., Sobkowicz B., Mroczko B., et al. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction // Clin. Chim. Acta. 2010. Vol. 411, N 23-24. P. 2014–2018. DOI: 10.1016/j.cca.2010.08.024Kuklinska A.M., Sobkowicz B., Sawicki R., et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction // Heart Vessels. 2010. Vol. 25. P. 363–367. DOI: 10.1007/s00380-009-1217-3Kuklinska A.M., Sobkowicz B., Sawicki R., et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction // Heart Vessels. 2010. Vol. 25. P. 363–367. DOI: 10.1007/s00380-009-1217-3Kadoglou N.P., Lampropoulos S., Kapelouzou A., et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease — KOZANI STUDY // Transl. Res. 2010. Vol. 155. P. 238–246. DOI: 10.1016/j.trsl.2010.01.004Kadoglou N.P., Lampropoulos S., Kapelouzou A., et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease — KOZANI STUDY // Transl. Res. 2010. Vol. 155. P. 238–246. DOI: 10.1016/j.trsl.2010.01.004Kleinz M.J., Baxter G.F. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase // Regul. Pept. 2008. Vol. 146. N 1-3. P. 271–277. DOI: 10.1016/j.regpep.2007.10.002Kleinz M.J., Baxter G.F. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase // Regul. Pept. 2008. Vol. 146. N 1-3. P. 271–277. DOI: 10.1016/j.regpep.2007.10.002Földes G., Horkay F., Szokodi I., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure // Am. J. Hypertens. 203. Vol. 16, N 5. A15. DOI: 10.1016/s0895-7061(03)00117-1Földes G., Horkay F., Szokodi I., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure // Am. J. Hypertens. 203. Vol. 16, N 5. A15. DOI: 10.1016/s0895-7061(03)00117-1Chong K.S., Gardner R.S., Morton J.J., et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure // Eur. J. Heart Fail. 2006. Vol. 8, N 4. P. 355–360. DOI: 10.1016/j.ejheart.2005.10.007Chong K.S., Gardner R.S., Morton J.J., et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure // Eur. J. Heart Fail. 2006. Vol. 8, N 4. P. 355–360. DOI: 10.1016/j.ejheart.2005.10.007Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction // Circulation. 2003. Vol. 108, N 12. P. 1432–1439. DOI: 10.1161/01.cir.0000091235.94914.75Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction // Circulation. 2003. Vol. 108, N 12. P. 1432–1439. DOI: 10.1161/01.cir.0000091235.94914.75Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action // Am. J. Physiol. Endocrin. Metab. 2006. Vol. 290, N 6. P. E1253–E1261. DOI: 10.1152/ajpendo.00572.2004Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action // Am. J. Physiol. Endocrin. Metab. 2006. Vol. 290, N 6. P. E1253–E1261. DOI: 10.1152/ajpendo.00572.2004de Souza Batista C.M., Yang R.Z., Lee M.J., et al. Omentin plasma levels and gene expression are decreased in obesity // Diabetes. 2007. Vol. 56, N 6. P. 1655–1661. DOI: 10.2337/db06-1506de Souza Batista C.M., Yang R.Z., Lee M.J., et al. Omentin plasma levels and gene expression are decreased in obesity // Diabetes. 2007. Vol. 56, N 6. P. 1655–1661. DOI: 10.2337/db06-1506Shibata R., Ouchi N., Kikuchi R., et al. Circulating omentin is associated with coronary artery disease in men // Atherosclerosis. 2011. Vol. 219, N 2. P. 811– 814. DOI: 10.1016/j.atherosclerosis.2011.08.017Shibata R., Ouchi N., Kikuchi R., et al. Circulating omentin is associated with coronary artery disease in men // Atherosclerosis. 2011. Vol. 219, N 2. P. 811– 814. DOI: 10.1016/j.atherosclerosis.2011.08.017Narumi T., Watanabe T., Kadowaki S., et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure // Cardiovasc. Diabetol. 2014. Vol. 13. P. 84. DOI: 10.1186/1475-2840-13-84Narumi T., Watanabe T., Kadowaki S., et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure // Cardiovasc. Diabetol. 2014. Vol. 13. P. 84. DOI: 10.1186/1475-2840-13-84Deo R., Khera A., McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis // J. Am. Coll. Cardiol. 2004. Vol. 44, N 9. P. 1812–1818. DOI: 10.1016/j.jacc.2004.07.047Deo R., Khera A., McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis // J. Am. Coll. Cardiol. 2004. Vol. 44, N 9. P. 1812–1818. DOI: 10.1016/j.jacc.2004.07.047Tang W., Pankow J.S., Carr J.J., et al. Association of sICAM-1 and MCP-1with coronary artery calcification in families enriched for coronary heart disease or hypertension: the NHLBI Family Heart Study // BMC Cardiovasc. Disord. 2007. Vol. 7, N 1. DOI: 10.1186/1471-2261-7-30Tang W., Pankow J.S., Carr J.J., et al. Association of sICAM-1 and MCP-1with coronary artery calcification in families enriched for coronary heart disease or hypertension: the NHLBI Family Heart Study // BMC Cardiovasc. Disord. 2007. Vol. 7, N 1. DOI: 10.1186/1471-2261-7-30de Lemos J.A., Morrow D.A., Blazing M.A., et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial // J. Am. Coll. Cardiol. 2007. Vol. 50, N 22. P. 2117–2124. DOI: 10.1016/j.jacc.2007.06.057de Lemos J.A., Morrow D.A., Blazing M.A., et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial // J. Am. Coll. Cardiol. 2007. Vol. 50, N 22. P. 2117–2124. DOI: 10.1016/j.jacc.2007.06.057Serrano-Martinez M., Palacios M., Lezaun R. Monocyte chemoattractant protein-1 concentration in coronary sinus blood and severity of coronary disease // Circulation. 2003. Vol. 108, N 10. P. e75. DOI: 10.1161/01.cir.0000089100.20182.b7Serrano-Martinez M., Palacios M., Lezaun R. Monocyte chemoattractant protein-1 concentration in coronary sinus blood and severity of coronary disease // Circulation. 2003. Vol. 108, N 10. P. e75. DOI: 10.1161/01.cir.0000089100.20182.b7de Lemos J., Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes // Circulation. 2003. Vol. 107, N 5. P. 690–695. DOI: 10.1161/01.cir.0000049742. 68848.99de Lemos J., Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes // Circulation. 2003. Vol. 107, N 5. P. 690–695. DOI: 10.1161/01.cir.0000049742. 68848.99Lee Y., Lee S., Jung E.S., et al. Visceral adiposity and the severity of coronary artery disease in middleaged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1 // Atherosclerosis. 2010. Vol. 213, N 2. P. 592–597. DOI: 10.1016/j.atherosclerosis.2010.09.012Lee Y., Lee S., Jung E.S., et al. Visceral adiposity and the severity of coronary artery disease in middleaged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1 // Atherosclerosis. 2010. Vol. 213, N 2. P. 592–597. DOI: 10.1016/j.atherosclerosis.2010.09.012Park S.E., Lee N.S., Park J.W., et al. Association of urinary RBP4 with insulin // Eur. J. Endocrinol. 2014. Vol. 171, N 4. P. 443–449. DOI: 10.1530/ EJE-14-0247Park S.E., Lee N.S., Park J.W., et al. Association of urinary RBP4 with insulin // Eur. J. Endocrinol. 2014. Vol. 171, N 4. P. 443–449. DOI: 10.1530/ EJE-14-0247Nikolaos P.E., Kadoglou N.P., Lambadiari V. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability // Atherosclerosis. 2014. Vol. 5. P. 606– 612. DOI: 10.1016/j.atherosclerosis.2014.05.957Nikolaos P.E., Kadoglou N.P., Lambadiari V. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability // Atherosclerosis. 2014. Vol. 5. P. 606– 612. DOI: 10.1016/j.atherosclerosis.2014.05.957Liu G., Ding M., Chiuve S.E., et al. Plasma levels of fatty acid–binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes. A 22-year prospective study // Arterioscler. Thromb. Vascular. Biol. 2016. Vol. 36. P. 2259– 2267. DOI: 10.1161/ATVBAHA.116.308320Liu G., Ding M., Chiuve S.E., et al. Plasma levels of fatty acid–binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes. A 22-year prospective study // Arterioscler. Thromb. Vascular. Biol. 2016. Vol. 36. P. 2259– 2267. DOI: 10.1161/ATVBAHA.116.308320Ingelsson E., Sundström J., Melhus H., et al. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly // Atherosclerosis, 2009. Vol. 206, N 1. P. 239–244. DOI: 10.1016/j.atherosclerosis.2009.02.029Ingelsson E., Sundström J., Melhus H., et al. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly // Atherosclerosis, 2009. Vol. 206, N 1. P. 239–244. DOI: 10.1016/j.atherosclerosis.2009.02.029Alkharfy K.M., Al-Daghri N.M., Vanhoutte P.M., et al. Serum Retinol-Binding Protein 4 as a Marker for Cardiovascular Disease in Women // PLoS One. 2012. Vol. 7, N 10. P. e48612. DOI: 10.1371/journal.pone.0048612Alkharfy K.M., Al-Daghri N.M., Vanhoutte P.M., et al. Serum Retinol-Binding Protein 4 as a Marker for Cardiovascular Disease in Women // PLoS One. 2012. Vol. 7, N 10. P. e48612. DOI: 10.1371/journal.pone.0048612Smekal A., Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2017. Vol. 161, N 1. P. 31–40. DOI: 10.5507/bp.2017.002Smekal A., Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2017. Vol. 161, N 1. P. 31–40. DOI: 10.5507/bp.2017.002

The authors declare that there are no conflicts of interest present.